Physician profile
Christopher E Title
NPI 1578068235
$22,858.95
in general payments reported to CMS, 2019-2025
39 companies · $5,234 in 2025
The $5,234 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,495 · 2022: $4,166 · 2023: $4,208 · 2024: $4,756 · 2025: $5,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,713.80 |
| Education | $484.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,931.94 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $3,228.06 | 2021-2025 | |
| Amgen INC. | $3,024.09 | 2021-2025 | Tavneos, Enbrel, Amjevita |
| Ucb, INC. | $2,808.44 | 2021-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $1,283.94 | 2021-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $1,167.43 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,147.19 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $711.47 | 2021-2024 | Taltz |
| Pfizer INC. | $456.84 | 2021-2025 | |
| Organon LLC | $424.81 | 2023-2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $371.49 | 2023-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.30 | 2021-2025 | Ofev, Cyltezo |
| Glaxosmithkline, LLC. | $341.72 | 2021-2023 | Benlysta |
| Fresenius Kabi USA, LLC | $270.49 | 2023-2025 | Idacio |
| Alexion Pharmaceuticals, INC. | $258.73 | 2021-2025 | Strensiq |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $253.55 | 2021-2022 | |
| Alvogen INC | $202.85 | 2022-2025 | Teriparatide |
| Radius Health, INC. | $200.94 | 2021-2025 | Tymlos |
| Genzyme Corporation | $194.94 | 2023-2025 | |
| Horizon Therapeutics Plc | $178.50 | 2021-2022 | |
| Sobi, INC | $155.03 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $136.05 | 2023 | Acthar |
| Genentech USA, INC. | $108.52 | 2021-2025 | Gazyva |
| Ferring Pharmaceuticals INC. | $107.38 | 2021-2023 | Euflexxa |
| Sandoz INC. | $92.14 | 2023-2025 | Hyrimoz, Jubbonti |
| Daiichi Sankyo INC. | $80.07 | 2021-2023 | Injectafer |
| Aurinia Pharma U.S., INC. | $61.65 | 2021-2023 | Lupkynis |
| Fidia Pharma USA INC. | $40.88 | 2022-2024 | Hymovis |
| Mylan Institutional INC. | $36.19 | 2023 | Hulio |
| Kyowa Kirin, INC. | $35.93 | 2023-2025 | Crysvita |
| Biohaven Pharmaceuticals, INC. | $32.67 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $30.66 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $28.48 | 2022-2023 | Uptravi, Opsumit |
| Tonix Medicines, INC. | $23.75 | 2025 | Tonmya |
| Teva Pharmaceuticals USA, INC. | $17.99 | 2021 | |
| Bioventus LLC | $17.75 | 2023 | Supartz Fx Sodium Hyaluronate |
| Takeda Pharmaceuticals U.S.A., INC. | $15.78 | 2023 | Hyqvia |
| Leo Pharma INC. | $14.93 | 2025 | Anzupgo |
| Antares Pharma, INC. | $14.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Title listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.